Pieris Pharmaceuticals to Host Third Quarter 2016 Investor Call and Corporate Update on November 10, 2016

Pieris Pharmaceuticals to Host Third Quarter 2016 Investor Call and Corporate Update on November 10, 2016

BOSTON, MA--(Marketwired - November 01, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, will host a third quarter 2016 investor conference call on Thursday, November 10, 2016 at 10:00 AM (EST) to discuss financial results and provide a corporate update.

To access the call, participants may dial 877-407-8920 (US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call.

An archived replay of the call will be available by dialling 877-660-6853 (US & Canada) or 201-612-7415 (International) and providing the Conference ID #: 13603006.

About Pieris

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is registered trademarks of Pieris. For more information, visit www.pieris.com. Anticalin®, Anticalins® are registered trademarks of Pieris.

Company Contact:
Pieris Pharmaceuticals, Inc.
Darlene Deptula-Hicks
SVP & Chief Financial Officer
+1-603-553-5803
[email protected]

Investor Relations Contact:
The Trout Group
Thomas Hoffmann
+1-646-378-2931
[email protected]

Media Inquiries:
Gretchen Schweitzer
+49 172 861 8540
[email protected]